Prediction of response to interferon therapy in multiple sclerosis

Acta Neurologica Scandinavica

Volumn 130, Issue 4, 2014, Pages 268-275

  Sellebjerg, F ^a   Sondergaard H B ^a   Koch Henriksen, N ^b,c   Sorensen P S ^a   Oturai, A B ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Interferon beta; Multiple sclerosis; Pharmacogenetics; Treatment response

Indexed keywords

BETA INTERFERON; GLYCOPROTEIN; GLYPICAN 5; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 5; UNCLASSIFIED DRUG; GLYPICAN; GPC5 PROTEIN, HUMAN; INTERFERON REGULATORY FACTOR; IRF5 PROTEIN, HUMAN;

ADULT; ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PREDICTION; PROSPECTIVE STUDY; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENT DISEASE;

ADULT; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLYPICANS; HUMANS; INTERFERON REGULATORY FACTORS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POLYMORPHISM, SINGLE NUCLEOTIDE; RECURRENCE;

EID: 84925351744     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12269     Document Type: Article

References (33)

1. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94.
2. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
3. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
4. Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol 2009;8: 545-59.
5. Hesse D, Krakauer M, Lund H et al. Breakthrough disease during interferon-beta therapy in MS: no signs of impaired biologic response. Neurology 2010;74:1455-62.
6. Rio J, Rovira A, Tintore M et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler 2008;14:479-84.
7. Rio J, Castillo J, Rovira A et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009;15:848-53.
8. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004;56:548-55.
9. O'Rourke K, Walsh C, Antonelli G, Hutchinson M. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler 2007;13:336-42.
10. Tomassini V, Paolillo A, Russo P et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006;253:287-93.
11. Prosperini L, Gallo V, Petsas N, Borriello G, Pozzilli C. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 2009;16:1202-9.
12. Pappas DJ, Oksenberg JR. Multiple sclerosis pharmacogenomics: maximizing efficacy of therapy. Neurology 2010;74(Suppl 1):S62-9.
13. Byun E, Caillier SJ, Montalban X et al. Genome-wide pharmacogenomic analysis of the response to interferon Beta therapy in multiple sclerosis. Arch Neurol 2008;65:337-44.
14. Cenit MD, Blanco-Kelly F, de las Heras V et al. Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler 2009;15:913-7.
15. Gross R, Healy BC, Cepok S et al. Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol 2011;233:168-74.
16. Vandenbroeck K, Alloza I, Swaminathan B et al. Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection. Genes Immun 2011;12:40-5.
17. Vosslamber S, van der Voort LF, van den Elskamp IJ et al. Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonbeta therapy in multiple sclerosis. Genes Immun 2011; 12:466-72.
18. Sorensen PS, Koch-Henriksen N, Ravnborg M et al. Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey. Mult Scler 2006;12:253-64.
19. Sormani MP, Rovaris M, Comi G, Filippi M. A composite score to predict short-term disease activity in patients with relapsing-remitting MS. Neurology 2007;69:1230-5.
20. Rio J, Nos C, Tintore M et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006;59:344-52.
21. Waubant E, Vukusic S, Gignoux L et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003;61:184-9.
22. Trojano M, Liguori M, Paolicelli D et al. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler 2003;9:451-7.
23. Martinez-Yelamos S, Martinez-Yelamos A, Martin OG, Casado V, Carmona O, Arbizu T. Regression to the mean in multiple sclerosis. Mult Scler 2006;12:826-9.
24. Sormani MP, Signori A, Siri P, De SN. Time to first relapse as an endpoint in multiple sclerosis clinical trials. Mult Scler 2013;19:466-74.
25. Sormani MP, Rio J, Tintore M et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 2013;19:605-12.
26. Sormani MP, Li DK, Bruzzi P et al. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology 2011;77:1684-90.
27. De Jager PL, Jia X, Wang J et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009;41:776-82.
28. Hafler DA, Compston A, Sawcer S et al. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J Med 2007;357:851-62.
29. Sawcer S, Hellenthal G, Pirinen M et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214-9.
30. Baranzini SE, Wang J, Gibson RA et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009;18:767-78.
31. Kristjansdottir G, Sandling JK, Bonetti A et al. Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet 2008;45:362-9.
32. Graham RR, Kozyrev SV, Baechler EC et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006;38:550-5.
33. Comabella M, Craig DW, Morcillo-Suarez C et al. Genome-wide scan of 500, 000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009;66:972-8.